CDC Votes To Add COVID-19 Vaccines To Childhood Immunization Schedule

October 20th, 2022

Via: The Defender:

The Centers for Disease Control and Prevention’s (CDC) independent vaccine advisory committee today voted unanimously (15-0) to recommend adding COVID-19 vaccines for children as young as 6 months old to the new Child and Adolescent Immunization Schedule, which will be rolled out in February 2023.

The revised recommendations accepted today by the committee include the Moderna or Pfizer-BioNTech COVID-19 vaccine for children as young as 6 months old and the Novavax COVID-19 vaccine for children as young as 12.

All COVID-19 vaccines being administered in the U.S. to people under 18 are Emergency Use Authorized (EUA) products. The U.S. Food and Drug Administration did grant full approval to Pfizer’s Comirnaty COVID-19 vaccine for ages 12 and older, however, the Comirnaty vaccine is not available in the U.S. — which means all children who get the Pfizer vaccine are getting an EUA product.

When asked if an EUA product could be added to the schedule, Dr. A. Patricia Wodi, a member of the CDC’s Advisory Committee on Immunization Practices (ACIP), said the U.S. Department of Justice Office of General Counsel confirmed for the CDC that EUA products can be added.

Commenting on Wodi’s statement, Dr. Meryl Nass said, “And that was that. No legal justification. No moral or ethical justification. And definitely no medical or scientific justification.”

Nass said she isn’t aware of any EUA product ever being added to the schedule until today.

More: CDC’s Advisory Committee on Immunization Practices Voted to Add Covid-19 Shots to Children’s Recommended Vaccine Schedule

More: Pfizer Increasing U.S. COVID Vaccine Price to $110-$130 Per Dose

Leave a Reply

You must be logged in to post a comment.